Leveraging Real-World Data to Support Drug and Diagnostic Assay Development in Molecular Oncology
Oct. 3, 2019 • Webinar 2pm ETRegister
The acquisition of N-of-One by QIAGEN in January 2019 brings together best-in-class solutions across multiple functional areas in molecular oncology. QIAGEN has established capabilities across the next-generation DNA sequencing and analysis process by using a world-class curated database to automate pathogenicity and actionability assessment. The addition of N-of-One's clinical interpretation will allow the delivery of a true “sample to insight” solution.
Join us to discuss the impact of real-world data on molecular oncology. This webinar will cover:
- How customers can leverage real-world data in clinical and scientific settings.
- How N-of-One and QIAGEN work together to deliver a true “sample to real-world insight” solution.
- How QIAGEN leverages N-of-One data to support biomarker selection decisions for diagnostic assays.